T&R Biofab Co. Ltd (KQ:246710) — Market Cap & Net Worth
Market Cap & Net Worth: T&R Biofab Co. Ltd (246710)
T&R Biofab Co. Ltd (KQ:246710) has a market capitalization of $47.03 Million (₩69.40 Billion) as of September 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22220 globally and #1401 in its home market, demonstrating a -1.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying T&R Biofab Co. Ltd's stock price ₩2275.00 by its total outstanding shares 30506586 (30.51 Million). Also see 246710 asset base for a full breakdown of the balance sheet.
T&R Biofab Co. Ltd Market Cap History: 2018 to 2026
T&R Biofab Co. Ltd's market capitalization history from 2018 to 2026. Data shows change from $92.10 Million to $47.03 Million (-12.14% CAGR). Also see T&R Biofab Co. Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
T&R Biofab Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$235.78 Billion | 0.02% | #673 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$235.78 Billion | 0.02% | #673 of 1384 |
Weight: T&R Biofab Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
T&R Biofab Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how T&R Biofab Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check T&R Biofab Co. Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.02x
T&R Biofab Co. Ltd's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $92.10 Million | $974.32 Million | -$4.69 Billion | 0.09x | N/A |
| 2019 | $103.37 Million | $1.29 Billion | -$6.25 Billion | 0.08x | N/A |
| 2020 | $174.18 Million | $6.81 Billion | -$5.60 Billion | 0.03x | N/A |
| 2021 | $518.91 Million | $3.23 Billion | -$11.08 Billion | 0.16x | N/A |
| 2022 | $236.72 Million | $5.75 Billion | -$10.34 Billion | 0.04x | N/A |
| 2023 | $184.62 Million | $5.20 Billion | -$13.42 Billion | 0.04x | N/A |
| 2024 | $89.62 Million | $4.87 Billion | -$7.68 Billion | 0.02x | N/A |
Competitor Companies of 246710 by Market Capitalization
Companies near T&R Biofab Co. Ltd in the global market cap rankings as of September 19, 2026. Review 246710 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to T&R Biofab Co. Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
T&R Biofab Co. Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, T&R Biofab Co. Ltd's market cap moved from $92.10 Million to $ 47.03 Million, with a yearly change of -12.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩47.03 Million | -41.82% |
| 2025 | ₩80.83 Million | -9.80% |
| 2024 | ₩89.62 Million | -51.46% |
| 2023 | ₩184.62 Million | -22.01% |
| 2022 | ₩236.72 Million | -54.38% |
| 2021 | ₩518.91 Million | +197.92% |
| 2020 | ₩174.18 Million | +68.50% |
| 2019 | ₩103.37 Million | +12.23% |
| 2018 | ₩92.10 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of T&R Biofab Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.03 Million USD |
| MoneyControl | $47.03 Million USD |
| MarketWatch | $47.03 Million USD |
| marketcap.company | $47.03 Million USD |
| Reuters | $47.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.